NCT03030378 2026-04-13
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
First Hospital of China Medical University
University of California, San Francisco
Mayo Clinic
National Cancer Institute (NCI)
University of California, San Francisco
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
City of Hope Medical Center
Jonsson Comprehensive Cancer Center
Mayo Clinic
M.D. Anderson Cancer Center
Stanford University